Digital monitoring platform vs standard care for metastatic triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study compares a digital health monitoring platform (Cureety Techcare) to standard care for people with metastatic triple-negative breast cancer who are starting their first treatment. The goal is to see if using the platform helps manage symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have metastatic triple-negative breast cancer (confirmed by biopsy).
- You must be starting your first treatment for metastatic cancer (not a previous treatment for early-stage cancer).
- You must be able to fill out web-based questionnaires and have access to a computer, tablet, or smartphone with internet.
- You must be willing to let the study use a digital monitoring platform called Cureety Techcare.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a digital tool (a smartphone app) to help women and men with early breast cancer manage side effects from hormone therapy. The goal is to improve quality of life during treatment.
This trial tests a platform where you can track your experiences and concerns about cancer medications. It aims to help you and your care team manage medication safety.
This trial tests whether combining regular medication safety checks with electronic tracking of side effects can improve quality of life and help reduce economic burden for people taking cancer pills. It’s for people starting oral cancer therapy and using connected technology to report symptoms.
This study tests whether using a wearable watch and smartphone app to track activity and fitness can help monitor health in people with hormone receptor–positive, HER2-negative metastatic breast cancer while they take standard hormone therapy plus palbociclib. It mainly requires that you are already on these medicines for at least three months and can use the devices reliably.
This trial studies how using a wearable device and smartphone app can help monitor your health during your first cancer treatment for advanced solid tumors. You will receive a known therapy (not a placebo), and the research team will collect real-world data to improve care.
This trial checks if switching hormone therapy when ctDNA levels rise can help women with ER+/HER2- metastatic breast cancer. ctDNA is a tumor signal found in blood that may show early signs of resistance before scans do.
Hear when a new Metastatic Triple-Negative Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.